Analysts Anticipate Ritter Pharmaceuticals Inc (RTTR) Will Announce Earnings of -$0.63 Per Share

Brokerages expect that Ritter Pharmaceuticals Inc (NASDAQ:RTTR) will announce earnings per share (EPS) of ($0.63) for the current quarter, according to Zacks. Zero analysts have made estimates for Ritter Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.76) and the highest estimate coming in at ($0.50). Ritter Pharmaceuticals posted earnings of ($1.40) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 55%. The firm is scheduled to issue its next earnings report on Monday, August 6th.

According to Zacks, analysts expect that Ritter Pharmaceuticals will report full year earnings of ($2.90) per share for the current financial year, with EPS estimates ranging from ($3.50) to ($2.29). For the next year, analysts expect that the company will report earnings of ($1.94) per share, with EPS estimates ranging from ($2.12) to ($1.75). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Ritter Pharmaceuticals.

Ritter Pharmaceuticals (NASDAQ:RTTR) last announced its quarterly earnings data on Tuesday, May 15th. The biotechnology company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01).

A number of research analysts have recently commented on RTTR shares. HC Wainwright set a $15.00 price objective on shares of Ritter Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, June 6th. Zacks Investment Research raised shares of Ritter Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.25 price objective for the company in a research report on Tuesday, May 8th. Finally, ValuEngine raised shares of Ritter Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Ritter Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $13.31.

Shares of Ritter Pharmaceuticals traded up $0.08, reaching $3.03, during midday trading on Thursday, according to MarketBeat.com. The stock had a trading volume of 21,203 shares, compared to its average volume of 105,470. Ritter Pharmaceuticals has a one year low of $1.80 and a one year high of $7.50. The company has a market cap of $14.96 million, a PE ratio of -0.61 and a beta of 0.74.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance.

Get a free copy of the Zacks research report on Ritter Pharmaceuticals (RTTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply